BioInsights Report - Gene Therapy 4.0: Crouching Before it Leaps – Despite Setbacks, Gene Therapy Field Continues to Advance
Senior research analyst and lead author Chris Raymond delivers an overview of the Piper Sandler biotech research team’s fourth annual BioInsights Gene Therapy Deep Dive, entitled: “Gene Therapy 4.0: Crouching Before it Leaps – Despite Setbacks, Gene Therapy Field Continues to Advance.”
This approximately 200-page report reviews recent setbacks and challenges – but also significant innovation and progress – in the gene therapy field. It details potential upcoming catalyst events for gene therapy companies and looks closely at the rich development landscape across a range of different approaches and serious disease indications.
More than 175 companies are mentioned within, and 24 key public and private players in the gene therapy space are profiled in detail, including Akouos, BioMarin Pharmaceutical Inc., MeiraGTx, Otonomy, Inc, Poseida Therapeutics, Inc., Solid Biosciences, Tenaya Therapeutics and Ultragenyx.
To access this report or learn more about the BioInsights report series, please reach out to your Piper Sandler contact or visit pipersandler.com/bioinsights.
September 2022 BioInsights report authored by Chris Raymond, Yasmeen Rahimi, PhD, Edward Tenthoff, Allison Bratzel, CFA, Nicole Gabreski, Ph.D., and Swapnil Malekar, PhD, MBA.
